RE:RE:RE:Minority Investor? Your optimistic view makes a lot of sense.
Some have been saying institutions are avoiding Onc for mangement or science reasons.
You are right on the $$ some institutions are restricted from buying below a certain price. The $5 number is one level.
hard to believe some institutions were not considering Ford motor (F), under $10, yet clamouring to buy into the teens & 20s.
That said, there are about 25+ institutions that do own shares of Onc( y).
Still, the trading price is way way out of synchronization with upside potential.
Should the science prove out, then the math becomes.
" what income can future sales of Pelareorep generate".....
THAT will be the cornerstone of a buy- out calculation.
partnership? Same math, the potential partner needs to see the opportunity for a return on investment.
again from the sale of the drug.
Note; The trading share price, as absolutely nothing to do with any if the future income potentials.
That comes from the sale of the drug.
Once the data comes out,.....assuming it is good activity will based on expectations , elevate the price.
Using your under $5, logic , once at that level, you will see significant movements.
Few, understand the upside speed & bredth of the movements.
being underweight with institutions is actually a great thing! Lots of share for them to become a part of.
Want to make exceptional $$$ on a stock. Find one very much under the radar, with huge upside.
Takes huge patience , balls of steel.
Ironically this weeks notice of a ASCO presentation was discussed, months ago.
Now, the market is reacting like it's something new!
The details being " oral presentation" is new. None the less. The smart $$ was buying last few months.
Just saying
.